Group 1 - Commerce Bancshares (CBSH) reported quarterly earnings of $1.14 per share, exceeding the Zacks Consensus Estimate of $1.02 per share, and showing an increase from $1.07 per share a year ago, resulting in an earnings surprise of +11.76% [1] - The company achieved revenues of $445.76 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.58%, compared to $414.49 million in the same quarter last year [2] - Over the last four quarters, Commerce has consistently surpassed consensus EPS and revenue estimates [2] Group 2 - The stock has added approximately 1.6% since the beginning of the year, while the S&P 500 has gained 6.2%, indicating underperformance relative to the broader market [3] - The current consensus EPS estimate for the upcoming quarter is $1.01 on revenues of $430.55 million, and for the current fiscal year, it is $4.08 on revenues of $1.72 billion [7] - The Zacks Industry Rank for Banks - Midwest is in the top 34% of over 250 Zacks industries, suggesting a favorable outlook for the industry [8]

Group 1: Earnings Performance - Byrna Technologies Inc. reported quarterly earnings of $0.1 per share, exceeding the Zacks Consensus Estimate of $0.05 per share, but down from $0.13 per share a year ago, representing an earnings surprise of +100.00% [1] - The company has surpassed consensus EPS estimates in all four of the last quarters [2] - Byrna Technologies posted revenues of $28.51 million for the quarter ended May 2025, slightly above the Zacks Consensus Estimate by 0.02%, and an increase from $20.27 million year-over-year [2] Group 2: Stock Performance and Outlook - Byrna Technologies shares have increased approximately 12.1% since the beginning of the year, outperforming the S&P 500's gain of 6.5% [3] - The future stock price movement will largely depend on management's commentary during the earnings call and the earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.06 on revenues of $26.5 million, and for the current fiscal year, it is $0.35 on revenues of $114.23 million [7] Group 3: Industry Context - The Technology Services industry, to which Byrna Technologies belongs, is currently ranked in the top 21% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]

Company Performance - Simply Good Foods reported quarterly earnings of $0.51 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.50 per share a year ago [1] - The company posted revenues of $380.96 million for the quarter ended May 2025, exceeding the Zacks Consensus Estimate by 0.23% and up from $334.76 million year-over-year [2] - Over the last four quarters, Simply Good Foods has surpassed consensus EPS estimates three times and has also topped consensus revenue estimates three times [1][2] Stock Outlook - Simply Good Foods shares have declined approximately 17% since the beginning of the year, contrasting with the S&P 500's gain of 6.5% [3] - The company's current consensus EPS estimate for the upcoming quarter is $0.49 on revenues of $376.45 million, and for the current fiscal year, it is $1.94 on revenues of $1.46 billion [7] Industry Context - The Food - Confectionery industry, to which Simply Good Foods belongs, is currently ranked in the bottom 11% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Simply Good Foods' stock performance [5]

Group 1 - Concentrix Corporation (CNXC) reported quarterly earnings of $2.7 per share, missing the Zacks Consensus Estimate of $2.76 per share, but showing an increase from $2.69 per share a year ago, resulting in an earnings surprise of -2.17% [1] - The company posted revenues of $2.42 billion for the quarter ended May 2025, surpassing the Zacks Consensus Estimate by 1.57%, and compared to year-ago revenues of $2.38 billion [2] - Concentrix shares have increased approximately 25.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 3.6% [3] Group 2 - The current consensus EPS estimate for the coming quarter is $2.88 on revenues of $2.39 billion, and for the current fiscal year, it is $11.57 on revenues of $9.56 billion [7] - The Zacks Industry Rank indicates that the Business - Services sector is currently in the top 27% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8]

Company Performance - Daktronics reported quarterly earnings of $0.18 per share, matching the Zacks Consensus Estimate, but down from $0.27 per share a year ago [1] - The company posted revenues of $172.55 million for the quarter ended April 2025, missing the Zacks Consensus Estimate by 14.19%, compared to $215.88 million in the same quarter last year [2] - Over the last four quarters, Daktronics has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2][3] Stock Outlook - Daktronics shares have declined approximately 9.9% since the beginning of the year, while the S&P 500 has gained 3.6% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $0.29 on revenues of $220.69 million, and for the current fiscal year, it is $1.02 on revenues of $814.44 million [7] - The estimate revisions trend for Daktronics was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Electronics - Miscellaneous Products industry, to which Daktronics belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, which may impact the stock's performance [8]

Company Overview - Exelixis shares have decreased by approximately 7.2% over the past month, underperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the key drivers affecting the stock [1] Earnings Estimates - Estimates for Exelixis have trended upward in the past month, with the consensus estimate shifting by 15.91% [2] VGM Scores - Exelixis has a strong Growth Score of A and a momentum score of A, with a value score of B, placing it in the top 40% for this investment strategy [3] - The aggregate VGM Score for Exelixis is A, indicating strong overall performance across multiple investment strategies [3] Outlook - The upward trend in estimates suggests a promising outlook for Exelixis, which holds a Zacks Rank 2 (Buy) [4] - An above-average return is expected from the stock in the upcoming months [4] Industry Performance - Exelixis is part of the Zacks Medical - Biomedical and Genetics industry, where Puma Biotech has gained 22.1% over the past month [5] - Puma Biotech reported revenues of $46 million for the last quarter, reflecting a year-over-year increase of 5% [5] - Puma Biotech's expected earnings for the current quarter are $0.11 per share, indicating a significant change of 320% from the previous year [6] - Puma Biotech also holds a Zacks Rank 2 (Buy) and has a VGM Score of A [6]

Group 1 - United Natural Foods (UNFI) reported quarterly earnings of $0.44 per share, exceeding the Zacks Consensus Estimate of $0.24 per share, and showing a significant increase from $0.10 per share a year ago, representing an earnings surprise of 83.33% [1] - The company achieved revenues of $8.06 billion for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 2.71% and increasing from $7.5 billion year-over-year [2] - United Natural has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] Group 2 - The stock has underperformed the market, losing about 5% since the beginning of the year, while the S&P 500 has gained 2.1% [3] - The company's earnings outlook is mixed, with current consensus EPS estimates at $0.19 for the coming quarter and $0.82 for the current fiscal year, with revenues expected to be $7.7 billion and $31.58 billion respectively [7] - The Zacks Industry Rank for Food - Miscellaneous is currently in the bottom 33% of over 250 Zacks industries, which may impact the stock's performance [8]

Financial Performance - MongoDB reported quarterly earnings of $1 per share, exceeding the Zacks Consensus Estimate of $0.65 per share, and up from $0.51 per share a year ago, representing an earnings surprise of 53.85% [1] - The company posted revenues of $549.01 million for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 4.23%, and an increase from $450.56 million year-over-year [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.59 on revenues of $546.56 million, and for the current fiscal year, it is $2.56 on revenues of $2.26 billion [7] - The estimate revisions trend for MongoDB is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Internet - Software industry, to which MongoDB belongs, is currently in the top 25% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Company Overview - Recursion Pharmaceuticals (RXRX) shares have increased by approximately 5.7% over the past month, underperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the stock's performance and potential catalysts [1] Earnings Estimates - Estimates for Recursion Pharmaceuticals have trended upward in the past month, with a consensus estimate shift of 10.13% [2] VGM Scores - The company has a poor Growth Score of F, a Momentum Score of A, and a Value Score of F, placing it in the bottom 20% for the value investment strategy [3] - The aggregate VGM Score for Recursion Pharmaceuticals is F, indicating a lack of focus on any single investment strategy [3] Outlook - The upward trend in estimates is promising, and Recursion Pharmaceuticals holds a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the coming months [4] Industry Comparison - Recursion Pharmaceuticals is part of the Zacks Medical - Drugs industry, where Ionis Pharmaceuticals (IONS) has gained 9.1% over the past month [5] - Ionis Pharmaceuticals reported revenues of $132 million for the last quarter, reflecting a year-over-year increase of 10.9% [5] - For the current quarter, Ionis Pharmaceuticals is expected to report a loss of $0.14 per share, indicating a 68.9% improvement from the previous year [6]

Core Viewpoint - Guidewire Software reported strong quarterly earnings of $0.88 per share, significantly exceeding the Zacks Consensus Estimate of $0.46 per share, and showing a substantial increase from $0.26 per share a year ago [1][2]. Financial Performance - The company achieved revenues of $293.51 million for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 2.73% and up from $240.68 million year-over-year [3]. - Guidewire Software has consistently outperformed consensus estimates, surpassing EPS estimates three out of the last four quarters and revenue estimates four times in the same period [2][3]. Stock Performance - Since the beginning of the year, Guidewire Software shares have increased by approximately 27.7%, in contrast to the S&P 500's gain of 0.9% [4]. - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7]. Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.59, with projected revenues of $331.29 million, while the estimate for the current fiscal year is $1.97 on revenues of $1.17 billion [8]. - The outlook for the Internet - Software industry is favorable, ranking in the top 22% of over 250 Zacks industries, suggesting potential for outperformance [9].